Last reviewed · How we verify

NCT06876727: EVAR_DAPT_SAPT

Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair

Completed Last updated 14 March 2025
What this trial tests

trial in Abdominal Aortic Aneurysms (AAA) in 8,325 participants. Completed in 30 September 2023.

Timeline
1 January 2003
Primary endpoint
30 September 2023
30 September 2023

Quick facts

Lead sponsorSamsung Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment8,325
Start date1 January 2003
Primary completion30 September 2023
Estimated completion30 September 2023

Conditions studied

Sponsor

Samsung Medical Center

Who can join

18 and older, any sex, with Abdominal Aortic Aneurysms (AAA) or Endovascular Aneurysm Repair (EVAR). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was a target trial emulation using the National Health Claims database established by the Korean National Health Insurance Service (K-NHIS). 8,325 patients were included.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Efficacy and Safety of Antiplatelet Therapy After Endovascular Aortic Repair: A Target Trial Emulation.
    Choi KH, Kang D, Nam J, Park TK, et al · · 2025 · PMID 41065286 · DOI 10.1161/jaha.125.044102

Verify or expand the search:

Other recruiting trials for Abdominal Aortic Aneurysms (AAA)

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06876727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing